Ocriplasmin is a recombinant fraction of plasmin with nonspecific protease activity capable of cleaving fibronectin and laminin. It has recently been approved for the treatment of vitreomacular traction and associated macular holes (MHs). Clinical trials1 report good clinical results and safety profile. We report 2 cases that developed zonular dehiscence at the time of vitrectomy and intraocular lens (IOL) implantation after treatment with ocriplasmin.
Keller J, Haynes RJ. Zonular Dehiscence at the Time of Combined Vitrectomy and Cataract Surgery After Intravitreal Ocriplasmin Injection. JAMA Ophthalmol. 2015;133(9):1091–1092. doi:10.1001/jamaophthalmol.2015.1680
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.